Loading...
The promise of CAR T-cell therapy in aggressive B-cell lymphoma
Relapsed or refractory aggressive B-cell lymphoma has an extremely poor prognosis and efforts to develop novel therapies for these patients have failed for almost four decades until the advent of chimeric antigen receptor (CAR) T-cell therapy. Within the last one year, two anti-CD19 CAR T-cell thera...
Saved in:
| Published in: | Best Pract Res Clin Haematol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2018
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6594830/ https://ncbi.nlm.nih.gov/pubmed/30213399 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.beha.2018.07.011 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|